Peer-reviewedCC BY-NC-NDJournal of thoracic disease
Reassessing perioperative risks: impact of neoadjuvant therapy on mortality in pneumonectomy
Related
- Is pneumonectomy appropriate after chemoimmunotherapy? Outcomes of neoadjuvant chemoimmunotherapy followed by pneumonectomy in the United States.
- Immune checkpoint inhibitors across neoadjuvant, perioperative, and adjuvant settings for resectable non-small-cell lung cancer: a systematic review and meta-analysis of randomized trials
- Neoadjuvant Chemotherapy and Perioperative Complications Associated with Pulmonary Toxicity.
- [Evolution of Perioperative Immunotherapy Paradigms in Non-small Cell Lung Cancer: From Adjuvant Dilemma to Neoadjuvant Priority].
- Reassessing adult surfactant replacement therapy with mechanics-informed reinforcement learning
BibTeX
@article{anon2026reassessing,
title = {{Reassessing perioperative risks: impact of neoadjuvant therapy on mortality in pneumonectomy}},
journal = {Journal of thoracic disease},
year = {2026},
month = aug,
url = {https://europepmc.org/article/PMC/PMC13655863},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Reassessing perioperative risks: impact of neoadjuvant therapy on mortality in pneumonectomy
PY - 2026
DA - 2026/08/14
JO - Journal of thoracic disease
UR - https://europepmc.org/article/PMC/PMC13655863
SN - 2072-1439
SN - 2077-6624
ER -